University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Emily Bergsland, M.D.

Gastrointestinal cancer specialist

Dr. Emily Bergsland is a specialist in gastrointestinal oncology at the UCSF Helen Diller Comprehensive Cancer Center. Her expertise includes treating colorectal and other gastrointestinal cancers, and neuroendocrine tumors. She sees patients in the Gastrointestinal Surgery and Oncology Clinic.

Bergsland earned a medical degree at the University of Minnesota and completed a residency and fellowship at UCSF. She joined the UCSF medical staff and faculty in 1996. In her research, she focuses on developing and testing new cancer therapies. She is a professor of clinical medicine at UCSF.

Clinics

Gastrointestinal Surgery and Oncology Clinic
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. – 5 p.m.

Pancreas Center
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone (Pancreatic Cancer): (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. — 5 p.m.

Conditions & Treatments

More about Emily Bergsland

Education

University of Minnesota 1989

Residencies

UCSF, Oncology 1995

Fellowships

UCSF, Internal Medicine 1992

Selected Research and Publications

  1. Bergsland EK, Nakakura EK. Neuroendocrine tumors of unknown primary: is the primary site really not known? JAMA Surg. 2014 Sep 1; 149(9):889-90.
  2. Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14.
  3. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell. 2014 Jun 16; 25(6):809-21.
  4. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. (90)Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80.
  5. Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland EK. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol. 2014 Apr; 73(4):695-702.
  6. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34.
  7. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600.
  8. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7.
  9. Bergsland EK. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):1-3.
  10. Bergsland EK. The evolving landscape of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):4-22.
  11. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7.
  12. Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012 Aug; 41(6):840-4.
  13. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun 1; 10(6):724-64.
  14. Paulson AS, Bergsland EK. Systemic therapy for advanced carcinoid tumors: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 1; 10(6):785-93.
  15. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25.
  16. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011 Jul; 254(1):97-102.
  17. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 1; 29(7):934-43.
  18. Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res. 2010 Sep; 163(1):47-51.
  19. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar; 145(3):276-80.
  20. Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer. 2010 Mar; 17(1):283-91.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.